Montelukast

Montelukast: Drug Information

Montelukast: Drug Information

Navigation
1. Drug Name
2. Pharmacological Class
3. Mechanism of Action
4. Indications
5. Dosage and Administration
6. Pharmacokinetics
7. Contraindications
8. Warnings and Precautions
9. Side Effects
10. Drug Interactions
11. Pregnancy and Lactation
12. Patient Counseling Information

1. Drug Name

Generic Name

Montelukast

Brand Name(s)

  • Pakistan: BrandX
  • India: BrandY
  • US: BrandZ
  • UK: BrandW

2. Pharmacological Class

Class

Leukotriene receptor antagonist

Subclass

Cysteinyl leukotriene receptor antagonist

3. Mechanism of Action

Montelukast selectively antagonizes the cysteinyl leukotriene receptor (CysLT1) and inhibits the actions of leukotriene D4 (LTD4) and other cysteinyl leukotrienes (LTC4 and LTE4) on the CysLT1 receptor. This action prevents bronchoconstriction, airway edema, and inflammation caused by these substances.

4. Indications

Primary Indications

  • Asthma, including prevention of daytime and nighttime symptoms
  • Allergic rhinitis

Off-label Uses

  • Exercise-induced bronchoconstriction
  • Chronic idiopathic urticaria

5. Dosage and Administration

Standard Dosage

The dosage of montelukast varies depending on the condition being treated and the age of the patient. Consult with a healthcare provider for specific dosing.

Route of Administration

Montelukast is administered orally as tablets or granules.

Special Populations

  • Pediatric: Dosing is age-dependent.
  • Geriatric: No dosage adjustment necessary based on age alone.

6. Pharmacokinetics

Absorption

Montelukast is well absorbed after oral administration.

Distribution

It is extensively bound to plasma proteins.

Metabolism

Metabolized extensively in the liver via CYP2C8 and CYP3A4.

Excretion

Excreted mainly via bile.

Half-life

The elimination half-life is approximately 2.7 to 5.5 hours.

7. Contraindications

Montelukast is contraindicated in patients with hypersensitivity to any component of the product.

8. Warnings and Precautions

  • Neuropsychiatric events have been reported; monitor for changes in behavior.
  • Eosinophilia and vasculitic rash have been reported; discontinue if these symptoms occur.
  • Churg-Strauss syndrome has been reported with montelukast use.

9. Side Effects

Common Side Effects

  • Headache
  • Abdominal pain
  • Thirst

Serious Side Effects

  • Hepatitis
  • Pancreatitis
  • Cholestatic hepatitis

10. Drug Interactions

Major Interactions

  • Phenobarbital
  • Rifampin

Moderate Interactions

  • Warfarin
  • Phenytoin

Minor Interactions

  • Aspirin
  • Fluconazole

11. Pregnancy and Lactation

Pregnancy Category

Category B - Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

Breastfeeding Considerations

It is not known whether montelukast is excreted in human milk, caution should be exercised when montelukast is administered to a nursing mother.

12. Patient Counseling Information

  • Take montelukast exactly as prescribed, even if you feel well.
  • Do not decrease your dose or stop taking montelukast without first talking to your healthcare provider.
  • Report any unusual symptoms to your healthcare provider immediately.

Post a Comment

Previous Post Next Post